Inventor · disambiguated record
John Round
Also filed as: ROUND JOHN · ROUND JOHN J
15 granted patents·20 pending applications·192 citations·filing 2014–2023
94Inventor score
Top patents by PatentIndex Score
35 records- 0198US9644180B2Synthetic membrane-receiver complexesRUBIUS THERAPEUTICS INC·Filed 2015·Granted May 9, 2017·98 cites·21 claims
- 0297US10344263B2Synthetic membrane-receiver complexesRUBIUS THERAPEUTICS INC·Filed 2017·Granted Jul 9, 2019·14 cites·25 claims
- 0397US10329531B2Synthetic membrane-receiver complexesRUBIUS THERAPEUTICS INC·Filed 2017·Granted Jun 25, 2019·18 cites·29 claims
- 0497US10253296B2Synthetic membrane-receiver complexesRUBIUS THERAPEUTICS INC·Filed 2017·Granted Apr 9, 2019·16 cites·24 claims
- 0596US10301594B1Synthetic membrane-receiver complexesRUBIUS THERAPEUTICS INC·Filed 2018·Granted May 28, 2019·11 cites·29 claims
- 0695US10301593B2Synthetic membrane-receiver complexesRUBIUS THERAPEUTICS INC·Filed 2018·Granted May 28, 2019·8 cites·27 claims
- 0794US10456421B2Compositions and methods related to engineered erythoid cells comprising 4-1BBLRUBIUS THERAPEUTICS INC·Filed 2017·Granted Oct 29, 2019·10 cites·20 claims
- 0893US10869898B2Methods and compositions for immunomodulationRUBIUS THERAPEUTICS INC·Filed 2015·Granted Dec 22, 2020·6 cites·25 claims
- 0992US10557119B2Erythroid cells comprising phenylalanine ammonia lyaseRUBIUS THERAPEUTICS INC·Filed 2019·Granted Feb 11, 2020·4 cites·27 claims
- 1092US10517897B1Methods related to engineered erythoid cells comprising 4-1BBLRUBIUS THERAPEUTICS INC·Filed 2019·Granted Dec 31, 2019·4 cites·28 claims
- 1190US10568910B2Compositions and methods related to engineered erythroid cells comprising IL-15RUBIUS THERAPEUTICS INC·Filed 2018·Granted Feb 25, 2020·3 cites·18 claims
- 1283US2023293588A1Compositions and Methods Related to Multimodal Therapeutic Cell Systems for Cancer IndicationsRUBIUS THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1378US2022072048A1Compositions and Methods Related to Multimodal Therapeutic Cell Systems for Autoimmune IndicationsRUBIUS THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1475US10716811B2Compositions and methods related to multimodal therapeutic cancer indicationsRUBIUS THERAPEUTICS INC·Filed 2018·Granted Jul 21, 2020·0 cites·20 claims
- 1575US2020002674A1Erythroid cells comprising phenylalanine hydroxylaseRUBIUS THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1675US2019309262A1Erythroid cells comprising serine dehydrataseRUBIUS THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1775US2019309261A1Erythroid cells comprising lysine oxidaseRUBIUS THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1875US2019316091A1Erythroid cells comprising arginaseRUBIUS THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1975US2019376034A1Platelets comprising exogenous polypeptides and uses thereofRUBIUS THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2075US2019316090A1Erythroid cells comprising arginine deiminaseRUBIUS THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2174US2019388473A1Methods and compositions for immunomodulationRUBIUS THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2272US2018216067A1Synthetic membrane-receiver complexesRUBIUS THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2372US2018265847A1Synthetic membrane-receiver complexesRUBIUS THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2471US2015182588A1Synthetic membrane-receiver complexesVL26 INC·Filed 2014·Application pending·0 cites
- 2571US2020129556A1Compositions and methods related to engineered erythroid cells comprising il-15RUBIUS THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2671US2018187153A1Synthetic membrane-receiver complexesRUBIUS THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2771US2018187154A1Synthetic membrane-receiver complexesRUBIUS THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2870US2018187155A1Compositions and methods related to multimodal therapeutic cell systems for autoimmune indicationsRUBIUS THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2966US11576934B2Methods and compositions for immunomodulationRUBIUS THERAPEUTICS INC·Filed 2019·Granted Feb 14, 2023·0 cites·20 claims
- 3066US2016257932A1Genetically engineered enucleated erythroid cells comprising a phenylalanine ammonia lyase receiver polypeptideRUBIUS THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 3163US11554141B2Methods and compositions for immunomodulationRUBIUS THERAPEUTICS INC·Filed 2018·Granted Jan 17, 2023·0 cites·18 claims
- 3259US12195638B2Compositions and methods of making a thin film and applications thereofALEO BME INC·Filed 2019·Granted Jan 14, 2025·0 cites·25 claims
- 3350US2019261627A1Biopolymeric germplasm integumentsALEO BME INC·Filed 2019·Application pending·0 cites
- 3443US2020172868A1Compositions and methods related to multimodal therapeutic cell systems for infectious diseaseRUBIUS THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 3542US2020172867A1Compositions and methods related to multimodal therapeutic cell systems for cardiometabolic diseaseRUBIUS THERAPEUTICS INC·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when John Round files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →